The ATMP landscape has been growing at a rapid rate since 2017, a momentous year in which three cell and gene therapies were approved—all the first of their kind.
Parkinson’s Disease. Diabetes. Muscular dystrophy. These diseases all lack cures, but they also share another important similarity: the quest for their cures is playing out in the field of ATMPs.